Non-small cell lung cancer with MET amplification: review of epidemiology, associated disease characteristics, testing procedures, burden, and treatments

Authors

Mo Yang
Erin Mandal
Frank X Liu
Richard M O'Hara
Beth Lesher
Rachel E Sanborn, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, United StatesFollow

Document Type

Article

Publication Date

1-1-2023

Publication Title

Front Oncol

Keywords

epidemiology; epithelial-mesenchymal transition; non-small cell lung carcinoma; systematic review; treatment outcome. oregon; chiles

Abstract

INTRODUCTION: Mesenchymal-epidermal transition factor gene amplification (

METHODS: Embase and Medline (via ProQuest), ClinicalTrials.gov, and Cochrane Controlled Register of Trials (2015-2022) were systematically searched. Conference abstracts were searched via Embase and conference proceedings websites (2020-2022). The review focused on evidence from the United States; global evidence was included for identified evidence gaps.

RESULTS: The median rate of primary

CONCLUSION: Primary

Clinical Institute

Cancer

Department

Oncology

Department

Epidemiology

Department

Pulmonary Medicine

Recommended Citation

Yang, Mo; Mandal, Erin; Liu, Frank X; O'Hara, Richard M; Lesher, Beth; and Sanborn, Rachel E, "Non-small cell lung cancer with MET amplification: review of epidemiology, associated disease characteristics, testing procedures, burden, and treatments" (2023). Articles, Abstracts, and Reports. 8481.
https://digitalcommons.providence.org/publications/8481